Zhong Guo Jing Ji Wang·2025-12-08 09:10Group 1 - The National Medical Products Administration of China announced on December 4 that 35 batches of drugs produced by 29 companies do not meet regulatory standards [1] - Among the non-compliant products, four batches of coenzyme Q10 injection produced by Jiangsu Wanbang Biopharmaceutical Group Co., Ltd. and others were flagged for issues related to appearance, insoluble particles, and visible foreign matter [1][2] - Specific batches of coenzyme Q10 injection from Jiangsu Wanbang Biopharmaceutical Group were identified with batch numbers 52401106 and 52404105, both showing non-compliance in multiple inspection criteria [1][2] Group 2 - Fosun Pharma's annual report indicates that Jiangsu Wanbang Biopharmaceutical Group Co., Ltd. is a wholly-owned subsidiary of the company [4] - For the first three quarters of 2025, Fosun Pharma reported a revenue of 29.393 billion yuan, a year-on-year decrease of 4.91%, while the net profit attributable to shareholders increased by 25.50% to 2.523 billion yuan [4] - The company's non-recurring net profit decreased by 14.32% to 1.573 billion yuan, and the stock option incentive plan did not include the declining revenue and non-recurring net profit as assessment indicators [4]